| . | CGL1 (n = 16) . | CGL2 (n = 11) . | P Value . |
|---|---|---|---|
| Age | 22 (11–31) | 11 (3–19) | .054 |
| Gender (F/M) | 10/6 (F: 62.5%) | 5/6 (F: 45.5%) | .452 |
| Diabetes | 9 (56.3%) | 5 (45.5%) | .704 |
| The median age when diabetes develops | 17 (12–37) | 15 (7.5–17.5) | .19 |
| Hypertriglyceridemia | 12 (75%) | 11 (100%) | .123 |
| The median age when hypertriglyceridemia detected | 14 (10–26) | 1 (0.5–11) | .003 |
| Low HDL cholesterol | 15 (93.8%) | 10 (90.9%) | .786 |
| Hepatic steatosis | 15 (93.8%) | 10 (90.9%) | .786 |
| The median age when hepatic steatosis detected | 16 (10–29) | 3.5 (0.5–13) | .007 |
| Elevated liver enzymes | 4 (25%) | 9 (81.8%) | .006 |
| Cirrhosis | 0 | 2 (18.2%) | .138 |
| Pancreatitis | 3 (18.8%) | 0 | .248 |
| Retinopathy | 5 (31.3%) | 2 (18.2%) | .662 |
| Nephropathy | 8 (50%) | 4 (36.4%) | .696 |
| Neuropathy | 5 (31.3%) | 1 (9.1%) | .35 |
| Atherosclerosis | 3 (18.8%) | 0 | .248 |
| Glucose (mmol/liter) | 7.11 (5.09–12.25) | 5.11 (4.56–8) | .076 |
| HbA1c (%) | 7 (5.5–9.7) | 5.9 (4.9–8.2) | .251 |
| HOMA score | 8.11 (3.47–16.39) | 12.46 (3.75–29.42) | .331 |
| Triglyceride (mmol/liter) | 6.01 (1.86–13.81) | 4.58 (2.88–7.64) | .882 |
| Total cholesterol (mmol/liter) | 4.42 (3.83–6.01) | 4.24 (3.64–5.92) | .748 |
| LDL cholesterol (mmol/liter) | 2.16 (1.24–2.73) | 2.53 (1.73–3.93) | .183 |
| HDL cholesterol (mmol/liter) | 0.75 (0.65–0.95) | 0.7 (0.41–0.86) | .277 |
| ALT (IU/liter) | 28 (23–41) | 75 (60–109) | .003 |
| AST (IU/liter) | 22 (17–33) | 43 (29–85) | .013 |
| GGT (IU/liter) | 24 (14–70) | 85 (53–178) | .007 |
| Leptin (ng/ml) | 0.74 (0.4–0.87) | 0.26 (0.1–0.57) | .008 |
| Adiponectin (μg/ml) | 0.67 (0.39–1.43) | 11.77 (6.81–19.29) | <.001 |
| . | CGL1 (n = 16) . | CGL2 (n = 11) . | P Value . |
|---|---|---|---|
| Age | 22 (11–31) | 11 (3–19) | .054 |
| Gender (F/M) | 10/6 (F: 62.5%) | 5/6 (F: 45.5%) | .452 |
| Diabetes | 9 (56.3%) | 5 (45.5%) | .704 |
| The median age when diabetes develops | 17 (12–37) | 15 (7.5–17.5) | .19 |
| Hypertriglyceridemia | 12 (75%) | 11 (100%) | .123 |
| The median age when hypertriglyceridemia detected | 14 (10–26) | 1 (0.5–11) | .003 |
| Low HDL cholesterol | 15 (93.8%) | 10 (90.9%) | .786 |
| Hepatic steatosis | 15 (93.8%) | 10 (90.9%) | .786 |
| The median age when hepatic steatosis detected | 16 (10–29) | 3.5 (0.5–13) | .007 |
| Elevated liver enzymes | 4 (25%) | 9 (81.8%) | .006 |
| Cirrhosis | 0 | 2 (18.2%) | .138 |
| Pancreatitis | 3 (18.8%) | 0 | .248 |
| Retinopathy | 5 (31.3%) | 2 (18.2%) | .662 |
| Nephropathy | 8 (50%) | 4 (36.4%) | .696 |
| Neuropathy | 5 (31.3%) | 1 (9.1%) | .35 |
| Atherosclerosis | 3 (18.8%) | 0 | .248 |
| Glucose (mmol/liter) | 7.11 (5.09–12.25) | 5.11 (4.56–8) | .076 |
| HbA1c (%) | 7 (5.5–9.7) | 5.9 (4.9–8.2) | .251 |
| HOMA score | 8.11 (3.47–16.39) | 12.46 (3.75–29.42) | .331 |
| Triglyceride (mmol/liter) | 6.01 (1.86–13.81) | 4.58 (2.88–7.64) | .882 |
| Total cholesterol (mmol/liter) | 4.42 (3.83–6.01) | 4.24 (3.64–5.92) | .748 |
| LDL cholesterol (mmol/liter) | 2.16 (1.24–2.73) | 2.53 (1.73–3.93) | .183 |
| HDL cholesterol (mmol/liter) | 0.75 (0.65–0.95) | 0.7 (0.41–0.86) | .277 |
| ALT (IU/liter) | 28 (23–41) | 75 (60–109) | .003 |
| AST (IU/liter) | 22 (17–33) | 43 (29–85) | .013 |
| GGT (IU/liter) | 24 (14–70) | 85 (53–178) | .007 |
| Leptin (ng/ml) | 0.74 (0.4–0.87) | 0.26 (0.1–0.57) | .008 |
| Adiponectin (μg/ml) | 0.67 (0.39–1.43) | 11.77 (6.81–19.29) | <.001 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT: γ-glutamyl transferase; LDL, low-density lipoprotein; NASH, nonalcoholic steatohepatitis.
Data are presented as median (25th–75th percentiles).
| . | CGL1 (n = 16) . | CGL2 (n = 11) . | P Value . |
|---|---|---|---|
| Age | 22 (11–31) | 11 (3–19) | .054 |
| Gender (F/M) | 10/6 (F: 62.5%) | 5/6 (F: 45.5%) | .452 |
| Diabetes | 9 (56.3%) | 5 (45.5%) | .704 |
| The median age when diabetes develops | 17 (12–37) | 15 (7.5–17.5) | .19 |
| Hypertriglyceridemia | 12 (75%) | 11 (100%) | .123 |
| The median age when hypertriglyceridemia detected | 14 (10–26) | 1 (0.5–11) | .003 |
| Low HDL cholesterol | 15 (93.8%) | 10 (90.9%) | .786 |
| Hepatic steatosis | 15 (93.8%) | 10 (90.9%) | .786 |
| The median age when hepatic steatosis detected | 16 (10–29) | 3.5 (0.5–13) | .007 |
| Elevated liver enzymes | 4 (25%) | 9 (81.8%) | .006 |
| Cirrhosis | 0 | 2 (18.2%) | .138 |
| Pancreatitis | 3 (18.8%) | 0 | .248 |
| Retinopathy | 5 (31.3%) | 2 (18.2%) | .662 |
| Nephropathy | 8 (50%) | 4 (36.4%) | .696 |
| Neuropathy | 5 (31.3%) | 1 (9.1%) | .35 |
| Atherosclerosis | 3 (18.8%) | 0 | .248 |
| Glucose (mmol/liter) | 7.11 (5.09–12.25) | 5.11 (4.56–8) | .076 |
| HbA1c (%) | 7 (5.5–9.7) | 5.9 (4.9–8.2) | .251 |
| HOMA score | 8.11 (3.47–16.39) | 12.46 (3.75–29.42) | .331 |
| Triglyceride (mmol/liter) | 6.01 (1.86–13.81) | 4.58 (2.88–7.64) | .882 |
| Total cholesterol (mmol/liter) | 4.42 (3.83–6.01) | 4.24 (3.64–5.92) | .748 |
| LDL cholesterol (mmol/liter) | 2.16 (1.24–2.73) | 2.53 (1.73–3.93) | .183 |
| HDL cholesterol (mmol/liter) | 0.75 (0.65–0.95) | 0.7 (0.41–0.86) | .277 |
| ALT (IU/liter) | 28 (23–41) | 75 (60–109) | .003 |
| AST (IU/liter) | 22 (17–33) | 43 (29–85) | .013 |
| GGT (IU/liter) | 24 (14–70) | 85 (53–178) | .007 |
| Leptin (ng/ml) | 0.74 (0.4–0.87) | 0.26 (0.1–0.57) | .008 |
| Adiponectin (μg/ml) | 0.67 (0.39–1.43) | 11.77 (6.81–19.29) | <.001 |
| . | CGL1 (n = 16) . | CGL2 (n = 11) . | P Value . |
|---|---|---|---|
| Age | 22 (11–31) | 11 (3–19) | .054 |
| Gender (F/M) | 10/6 (F: 62.5%) | 5/6 (F: 45.5%) | .452 |
| Diabetes | 9 (56.3%) | 5 (45.5%) | .704 |
| The median age when diabetes develops | 17 (12–37) | 15 (7.5–17.5) | .19 |
| Hypertriglyceridemia | 12 (75%) | 11 (100%) | .123 |
| The median age when hypertriglyceridemia detected | 14 (10–26) | 1 (0.5–11) | .003 |
| Low HDL cholesterol | 15 (93.8%) | 10 (90.9%) | .786 |
| Hepatic steatosis | 15 (93.8%) | 10 (90.9%) | .786 |
| The median age when hepatic steatosis detected | 16 (10–29) | 3.5 (0.5–13) | .007 |
| Elevated liver enzymes | 4 (25%) | 9 (81.8%) | .006 |
| Cirrhosis | 0 | 2 (18.2%) | .138 |
| Pancreatitis | 3 (18.8%) | 0 | .248 |
| Retinopathy | 5 (31.3%) | 2 (18.2%) | .662 |
| Nephropathy | 8 (50%) | 4 (36.4%) | .696 |
| Neuropathy | 5 (31.3%) | 1 (9.1%) | .35 |
| Atherosclerosis | 3 (18.8%) | 0 | .248 |
| Glucose (mmol/liter) | 7.11 (5.09–12.25) | 5.11 (4.56–8) | .076 |
| HbA1c (%) | 7 (5.5–9.7) | 5.9 (4.9–8.2) | .251 |
| HOMA score | 8.11 (3.47–16.39) | 12.46 (3.75–29.42) | .331 |
| Triglyceride (mmol/liter) | 6.01 (1.86–13.81) | 4.58 (2.88–7.64) | .882 |
| Total cholesterol (mmol/liter) | 4.42 (3.83–6.01) | 4.24 (3.64–5.92) | .748 |
| LDL cholesterol (mmol/liter) | 2.16 (1.24–2.73) | 2.53 (1.73–3.93) | .183 |
| HDL cholesterol (mmol/liter) | 0.75 (0.65–0.95) | 0.7 (0.41–0.86) | .277 |
| ALT (IU/liter) | 28 (23–41) | 75 (60–109) | .003 |
| AST (IU/liter) | 22 (17–33) | 43 (29–85) | .013 |
| GGT (IU/liter) | 24 (14–70) | 85 (53–178) | .007 |
| Leptin (ng/ml) | 0.74 (0.4–0.87) | 0.26 (0.1–0.57) | .008 |
| Adiponectin (μg/ml) | 0.67 (0.39–1.43) | 11.77 (6.81–19.29) | <.001 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT: γ-glutamyl transferase; LDL, low-density lipoprotein; NASH, nonalcoholic steatohepatitis.
Data are presented as median (25th–75th percentiles).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
